Identify high-risk members before they deteriorate
PhysioSense's UVPA platform gives health plans and care management teams a continuous, physiologically grounded signal for cardiovascular risk — enabling proactive intervention, reduced readmissions, and measurable cost savings.
Standard risk scores miss the patients who matter most
Claims-based models are retrospective, lag by months, and cannot detect the physiological precursors of acute events. Members with normal labs and stable vital signs can still be in compensated hemodynamic decline.
- Heart failure readmissions frequently occur within 30 days of discharge — often in members flagged as "stable" at follow-up
- CKD progression to end-stage renal disease correlates with vascular stiffening detectable months before eGFR decline
- Dementia-associated cardiovascular signatures appear in waveform data well before cognitive symptom onset
- Hypertension treatment response varies widely — standard BP targets miss many non-responders
A new physiological layer for care management
PhysioSense delivers a continuous vascular phenotype for each enrolled member using existing wearables and medical devices — no new hardware required for many deployments.
Where PhysioSense creates value for health plans
From chronic disease management to post-acute transitions, UVPA-derived signals layer onto existing care programs with minimal workflow disruption.
CHF Readmission Prevention
Early hemodynamic compensation is detectable in photoplethysmographic waveforms before clinical decompensation. PhysioSense identifies members whose vascular load and compliance are shifting — triggering timely outreach, medication titration, or escalation before a 911 call or ER visit.
CKD Progression Monitoring
Arterial stiffening — a hallmark of CKD-associated cardiovascular disease — is captured in waveform-derived compliance measures months before eGFR-based staging moves. PhysioSense enables earlier nephrology referral and cardiac co-management, protecting both kidneys and outcomes.
Cognitive Risk & Vascular Dementia
Vascular contributions to dementia — including reduced cerebral perfusion reserve and elevated central pulse pressure — are measurable in peripheral waveform signals. PhysioSense provides a cardiovascular risk layer complementary to cognitive assessments, informing prevention program enrollment.
Hypertension Treatment Response
BP targets alone are insufficient — vascular compliance and load responses to antihypertensives vary substantially by phenotype. PhysioSense identifies the physiological subgroup of each member, enabling precision titration rather than protocol-driven escalation.
Diabetic Cardiovascular Stratification
Cardiovascular disease is the leading cause of mortality in type 2 diabetes. UVPA-derived vascular phenotyping stratifies diabetic members by actual hemodynamic risk — enabling targeted SGLT2i/GLP-1 enrollment, preventive cardiology referral, and care plan intensification for truly high-risk individuals.
Discharge-to-Home Monitoring
The 30-day window post-hospitalization is the highest-risk period for readmission. PhysioSense's remote monitoring module provides a physiological early-warning layer during this transition — integrated with existing care coordination workflows and EHR messaging for nurse follow-up triggers.
Signal fidelity validated across clinical settings
PhysioSense's vascular phenotyping is grounded in research conducted across ICU, surgical, and ambulatory patient populations.
Hemodynamic Decompensation Detection
In patient populations monitored during acute care, UVPA-derived vascular state variables tracked hemodynamic trends consistent with physician-assessed clinical status. The kinetic decomposition framework captured progression patterns that preceded standard clinical thresholds, offering earlier intervention windows.
Arterial Stiffness Characterization
Across diverse patient cohorts, PhysioSense vascular compliance metrics correlated with established markers of arterial stiffness and cardiovascular risk. The approach detected compliance differences between clinically distinct patient groups with statistical separation not achievable using heart rate or SpO2 alone.
Medication Response Tracking
Serial waveform captures before and after hemodynamic interventions revealed consistent, directional vascular state changes aligned with known pharmacological mechanisms. The vascular phenotype responded measurably to antihypertensives, diuretics, and vasoactive agents — supporting use as a treatment response biomarker.
How health plans engage with PhysioSense
We structure engagements to move from proof-of-concept to program integration within a defined timeline, with clear decision gates.
Discovery & Cohort Definition
Jointly identify the highest-value member population — typically a chronic disease cohort with upcoming plan year risk. Define signal sources (wearables, RPM devices, biometric vendors already contracted).
Pilot Program (10–14 Weeks)
Deploy UVPA signal processing on enrolled pilot members. Generate vascular phenotype profiles, risk stratification outputs, and care management alerts. Measure against existing risk score for incremental lift.
Clinical Integration
Embed PhysioSense risk signals into existing care management platforms (Jiva, HealthEdge, Salesforce Health Cloud, etc.) via API. Configure care coordinator alert thresholds and outreach workflows.
Program Scaling & ROI Measurement
Expand to additional lines of business and member segments. Track readmission rates, ER utilization, and care management touchpoint efficiency as primary ROI metrics.
PhysioSense's contribution to a payer partnership
- UVPA kinetic decomposition engine — patent-protected signal processing across 6 domain areas
- Device-agnostic waveform ingestion layer (PPG, arterial line, radar, optical sensors)
- PulseVu enterprise platform: member-level dashboards, risk stratification, alert queuing
- API layer for EHR and care management system integration (HL7 FHIR compatible)
- Clinical AI validation — results interpretable by care managers without signal processing expertise
- IP portfolio available for licensing under NDA — supports proprietary payer product development
Ready to explore a pilot?
Schedule a briefing with our team — we'll walk through a pilot design specific to your highest-priority member cohort.
Request a Partnership Briefing